News archive
Showing 680 results
November 2010
-
Media Release
Novartis Pharmaceuticals Corporation restructuring US field force to align with changing product portfolio and strategic growth priorities
Elimination of 1,400 General Medicines field force positions effective January 1 to align organization with changes in portfolio and evolving healthcare market New organizational alignment creates… -
Media Release
Novartis Pharmaceuticals Corporation restructuring US field force to align with changing product portfolio and strategic growth priorities
-
Media Release
New “Stand Together for AD” campaign provides strength, support and important resources for 11 million Alzheimer’s caregivers
“Stand Together for AD: Strength and Support for Alzheimer’s” at AlzheimersDisease.com empowers caregivers with new resources and tools to help navigate challenges of caring for a loved one with… -
Media Release
New “Stand Together for AD” campaign provides strength, support and important resources for 11 million Alzheimer’s caregivers
October 2010
-
Media Release
Analysis shows Novartis drug TOBI® associated with reduced mortality in cystic fibrosis patients with common lung infection
- Review of data from more than 12,000 people in Cystic Fibrosis Foundation's Patient Registry shows 21% mortality reduction in patients treated with TOBI- TOBI is a widely used inhaled antibiotic… -
Media Release
Analysis shows Novartis drug TOBI® associated with reduced mortality in cystic fibrosis patients with common lung infection
September 2010
-
Media Release
Novartis gains FDA approval for Gilenya™, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
Gilenya is the first approved oral treatment indicated for relapsing forms of MS in the US, a major advance for people with this diseaseGilenya showed superior efficacy by reducing relapses by 52% at… -
Media Release
Novartis gains FDA approval for Gilenya™, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
August 2010
-
Media Release
Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure
-- Tekamlo combines in a single-pill the only approved direct renin inhibitor, Tekturna, with the widely prescribed calcium channel blocker, amlodipine-- Data showed Tekamlo significantly reduced… -
Media Release
Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure